Endocrine Abstracts

The observation that acquired GnRH deficiency and estrogen deficiency leadsto decreased bone mass in young women was critical evidence thathypothalamic/pituitary disorders could impact on bone metabolism in adults.A three-fold risk of fractures in adults with growth hormone deficiency(GHD) has led to the investigation of the role of the GH/IGF-I axis in bonemetabolism. Two human experimental models, acquired GHD and acquired GHresistance due to severe w...

Anne Klibanski, Massachusetts General Hospital, Boston, MA, USA AbstractAnne Klibanski, M.D, is Professor of Medicine, Harvard Medical School and Chief, Neuroendocrine Unit and Director of the Neuroendocrine Clinical Center at Massachusetts General Hospital, Boston. A leader in the field of neuroendocrinology, Dr. Klibanski's research interests include the pathogenesis of hypogonadal osteoporosis, neuroendocrine contro...

Two medical therapies are now available for the treatment of acromegaly. Pegvisomant is a growth hormone (GH) receptor antagonist. Somatostatin analogues, in contrast, act by inhibiting the release of GH from the pituitary. The primary objective of this study was to compare the efficacy of pegvisomant (P) to that of octreotide LAR (LAR) in terms of IGF-1 normalisation. The secondary objective was to compare safety and tolerability between the two treatments.<p class="abste...

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid tumours, and neuroendocrine tumours (NETs) of the pituitary and pancreas. MEN1 is caused by mutations of the tumour suppressor gene MEN1, and MEN1 germline mutations are found in >75% of MEN1 patients. The remaining 25% of patients may have mutations involving as yet unidentified gene...

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid tumours, and neuroendocrine tumours (NETs) of the pituitary and pancreas. MEN1 is caused by mutations of the tumour suppressor gene MEN1, and MEN1 germline mutations are found in >75% of MEN1 patients. The remaining 25% of patients may have mutations involving as yet unidentified gene...